[1] SHanab AA,Scully P,Crosbie O,et al.Small intestinal bacterial overgrowth in non-alcoholic steatohepatitis:association with Toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci,2011,56(5) :1524-1534. [2] Targher G,Day CP,Bonor a E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med,2010,363(14):1341-1350. [3] 李笠,梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性脂肪肝患者初步临床研究. 实用肝脏病杂志,2017,20(4):412-415. [4] Hung B,Ban X,He J,et al.Comparative analysis of essential oil components and antioxidant activity of extracts of Nelumbo nucifera from various areas of China. Agric Food Chem,2010,58(1):441-448. [5] Lin Z,Tian H,Lam KS,et al.Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab,2013,17(5):779-789. [6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3. [7] Drab SR.Clinical studies of liraglutide,a novel,oncedaily human glucagons-like peptide-1 analog for improved management of type 2 diabetes mellitus. Pharmacotherapy,2009,29(12Pt2):43S-54S. [8] 刘晓琳,范建高. 2017年亚太地区肝病年会非酒精性脂肪性肝病研究报道. 实用肝脏病杂志,2017,20(3):387-390. [9] Kharitonenkov A,Wroblewski VJ,Koester A,et al.The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.Endocrinology,2007,148(2):774-781. [10] Ogawa Y,Kurosu H,Yamamoto M,et al.Beta Klotho is required for metabolic activity of fibroblast growthfactor-2l. Proc Natl Acad Sci USA,2007,104(18):7432-7437. [11] Shih MH,Lazo M,Liu SH,et al.Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc,2015,114(4):314-320. [12] 杨林辉,郭昭友,曹明,等. 枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素水平的影响. 实用肝脏病杂志,2012,15(2):101-103. [13] Li W,Zhu C,Wu Y,et al.Increased Pygo2 expression in liver of patients with hepatitis B virus related fibrosis. Liver Int,2015,35(12):2522-2529. [14] Xu C,Wan X,Xu L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds. J Hepatol,2015,62(6):1412-1419. [15] Gwak GY,Moon TG,Lee DH,et al.Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol,2012,18(7):679-684. [16] Sun DQ,Wu SJ,Liu WY,et al.Serum uric acid:a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets,2016,20(3):3759387. [17] 管红雨,蔡晓波,陆伦根. 缺氧对非酒精性脂肪性肝病发病的影响. 实用肝脏病杂志,2016,19(2):237-240. [18] Yuan H,Yu C,Li X,et al.Serum uric acid levels and risk of metabolic syndrome:a dose-response Meta-analysis of prospective studies. J Clin Endocrinol Metab,2015,200(11):4198-4207. [19] Sirota JC,Mcfann K,Targher G,et al.Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States:liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism,201362(3):392-399. [20] 陈海姣,刘鹏飞,张伟,等. HIF-1α、NF-κB在大鼠不同程度非酒精性脂肪肝中的表达. 世界华人消化杂志,2014,22(35):5480-5485. |